Patheon Inc. (TSX: PTI) today announced the appointment of Mr. Douglas L. Ludwig to the position of Chief Financial Officer and Executive Vice-President.
“Doug is an integral addition to the senior leadership of Patheon,” said Mr. Robert Tedford, Chief Executive Officer. “Doug’s extensive experience as a proven Chief Financial Officer with an excellent reputation positions him to make a significant contribution to Patheon as we embark upon the next phase of profitable growth for the company. Doug’s recognized leadership skills, depth of public company experience, and international business expertise in the global service industry make him perfectly suited to contribute to the future success of Patheon.”
Mr. Rodger Roden has left the Company today to pursue other interests.
“On behalf of Patheon, I thank Rodger for his contributions to Patheon and I wish him every success in his future endeavours,” said Mr. Tedford.
Mr. Ludwig is a Chartered Accountant with more than 25 years of finance experience. Most recently, Mr. Ludwig served as Chief Financial Officer and Executive Vice-President of Four Seasons Hotels Inc. Mr. Ludwig’s 22-year career with Four Seasons covered many key positions within the corporate finance organization. Previously, Mr. Ludwig worked with KPMG for seven years after graduating from the Ivey School of Business at the University of Western Ontario. In his new position at Patheon, Mr. Ludwig will report to Mr. Tedford, Chief Executive Officer.
“Doug will assume full responsibility for the financial affairs of the company and communications with the financial community and related responsibilities,” said Mr. Tedford. “This reallocation of responsibilities will allow me to focus on enhancing our strategic client relationships and Patheon’s leadership position in our industry.”
Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,900 people and serving a client base of more than 200 pharmaceutical and biotechnology companies.
